These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 19726108)

  • 41. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    Bhatt DL; Topol EJ;
    Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A revised health impact assessment of increased use of aspirin in Wales.
    Morgan G
    Public Health; 2012 Aug; 126(8):719-20. PubMed ID: 22613028
    [No Abstract]   [Full Text] [Related]  

  • 43. Aspirin: real benefits, but real risks, too.
    Harv Heart Lett; 1999 May; 9(9):1-3. PubMed ID: 10200029
    [No Abstract]   [Full Text] [Related]  

  • 44. Platelet inhibitors: what are the data in women?
    Tempelhof MW; Newby LK
    Cardiol Rev; 2008; 16(1):23-9. PubMed ID: 18091399
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Primary cardiovascular prevention with aspirin].
    Seguí Díaz M; Escobar C; Divisón JA
    Semergen; 2015; 41(5):279-81. PubMed ID: 25622997
    [No Abstract]   [Full Text] [Related]  

  • 46. Chronic aspirin therapy for the prevention of cardiovascular events: a waste of time, or worse?
    Cleland JG
    Nat Clin Pract Cardiovasc Med; 2006 May; 3(5):234-5. PubMed ID: 16645645
    [No Abstract]   [Full Text] [Related]  

  • 47. Aspirin in the primary prevention of vascular disease.
    Ambrosi P
    Lancet; 2009 Sep; 374(9693):877; author reply 879. PubMed ID: 19748391
    [No Abstract]   [Full Text] [Related]  

  • 48. Low-dose aspirin for primary prevention of cardiovascular disease.
    Bredie SJ; Wollersheim H; Verheugt FW; Thien T
    Semin Vasc Med; 2003 May; 3(2):177-84. PubMed ID: 15199480
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aspirin resistance: is it real? Is it clinically significant?
    Dalen JE
    Am J Med; 2007 Jan; 120(1):1-4. PubMed ID: 17208069
    [No Abstract]   [Full Text] [Related]  

  • 50. Can the time of taking aspirin influence the frequency of cardiovascular events?
    Kriszbacher I; Ajtay Z; Koppán M; Bódis J
    Am J Cardiol; 2005 Aug; 96(4):608-10. PubMed ID: 16098324
    [No Abstract]   [Full Text] [Related]  

  • 51. Should patients stop taking aspirin for primary prevention?
    Depta JP; Bhatt DL
    Cleve Clin J Med; 2015 Feb; 82(2):91-6. PubMed ID: 25897597
    [No Abstract]   [Full Text] [Related]  

  • 52. Would it be more beneficial to take aspirin in the evening for prevention of cardiovascular diseases?
    Kriszbacher I; Koppán M; Bódis J
    J Vasc Surg; 2005 Feb; 41(2):375. PubMed ID: 15768027
    [No Abstract]   [Full Text] [Related]  

  • 53. Lowering cardiac risk in noncardiac surgery.
    Ehlers R; Felbinger TW; Eltzschig HK
    N Engl J Med; 2002 Apr; 346(14):1096-7. PubMed ID: 11932484
    [No Abstract]   [Full Text] [Related]  

  • 54. Aspirin in the secondary prevention of cardiovascular disease.
    Parekh AK; Galloway JM; Hong Y; Wright JS
    N Engl J Med; 2013 Jan; 368(3):204-5. PubMed ID: 23323896
    [No Abstract]   [Full Text] [Related]  

  • 55. Aspirin reduces cardiovascular events in primary prevention of cardiovascular disease but at a near equivalent risk of increased bleeding.
    Miedema MD; Virani SS
    Evid Based Med; 2016 Dec; 21(6):225. PubMed ID: 27780831
    [No Abstract]   [Full Text] [Related]  

  • 56. The role of aspirin in cardiovascular disease prevention.
    Wagenaar P
    Cardiovasc J Afr; 2012 Jun; 23(5):300. PubMed ID: 23077735
    [No Abstract]   [Full Text] [Related]  

  • 57. Population and individual health: the two faces of Janus.
    Goodyear-Smith F
    J Prim Health Care; 2010 Jun; 2(2):90-1. PubMed ID: 20690296
    [No Abstract]   [Full Text] [Related]  

  • 58. [Use of aspirin for primary prevention of cardiovascular events in diabetic patients--is it justified?].
    Benhamou Y; Lévesque H
    Rev Med Interne; 2009 Dec; 30(12):1001-3. PubMed ID: 19833416
    [No Abstract]   [Full Text] [Related]  

  • 59. Trials of primary prevention of cardiovascular events using aspirin.
    Kappagoda CT; Amsterdam EA
    Am J Cardiol; 2011 Oct; 108(8):1198-200. PubMed ID: 21985953
    [No Abstract]   [Full Text] [Related]  

  • 60. Aspirin for everyone over 50? Don't forget aspirin resistance.
    Dhatariya KK
    BMJ; 2005 Jul; 331(7509):161; author reply 161. PubMed ID: 16020867
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.